Pig pancreatic cell transplant improved outcomes in diabetics

05/7/2010 | Bloomberg Businessweek

No adverse events or immune system reactions were seen in patients with Type 1 diabetes who were transplanted with encapsulated pig pancreatic cells, according to a New Zealand study. After the treatment, two people were able to halt insulin shots for four weeks and 32 weeks, respectively, while others were able to lessen their daily insulin needs, the study also showed. The transplanted cells work by producing insulin in response to the high sugar levels in the patients' blood.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA